Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388338 | 0.82 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1TDP1USP2POLB | |
| SCHEMBL9912330 | 0.81 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1TDP1USP2POLB | |
| SCHEMBL14038379 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL13696400 | 0.72 | DOT1L (0.35) | SMN1; SMN2ALDH1A1USP2POLBALOX15 | |
| SCHEMBL9912317 | 0.72 | DOT1L (0.35) | SMN1; SMN2ALDH1A1USP2POLBALOX15 | |
| SCHEMBL13532238 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL12388333 | 0.70 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TDP1USP2POLB | |
| SCHEMBL13532236 | 0.69 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1USP2POLBALOX15 | |
| SCHEMBL14406304 | 0.67 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1TDP1TSHR | |
| SCHEMBL9912314 | 0.67 | PIK3CD (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | SMN1; SMN2 2147/4885ALDH1A1 2126/4885TDP1 1008/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | SMN1; SMN2 1206/4885ALDH1A1 1604/4885TDP1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.